领航医药生物科技(00399)拟收购Niraxx. Inc.大多数股权

智通财经11-12

智通财经APP讯，领航医药生物科技(00399)公布，于2024年11月12日，该公司作为投资者已与目标(Niraxx. Inc.)订立谅解备忘录，表明公司有意就有关目标的大多数股权的潜在投资对目标进行投资。据悉，目标为一间于美国德拉瓦州注册成立的有限公司，主要从事(a)开发人工智能驱动的虚拟健康平台SyncWell;(b)开发脑神经技术服务平台DeepSynaps;(c) 于运动服融入光生物调节...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2482702214?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-12 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482702214","market":"sh","top_or_hot":-1,"title":"领航医药生物科技(00399)拟收购Niraxx. Inc.大多数股权","media":"智通财经","content":"<div>\n<p>智通财经APP讯，领航医药生物科技(00399)公布，于2024年11月12日，该公司作为投资者已与目标(Niraxx. Inc.)订立谅解备忘录，表明公司有意就有关目标的大多数股权的潜在投资对目标进行投资。据悉，目标为一间于美国德拉瓦州注册成立的有限公司，主要从事(a)开发人工智能驱动的虚拟健康平台SyncWell;(b)开发脑神经技术服务平台DeepSynaps;(c) 于运动服融入光生物调节...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1210081.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>领航医药生物科技(00399)拟收购Niraxx. Inc.大多数股权</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n领航医药生物科技(00399)拟收购Niraxx. Inc.大多数股权\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-12 21:21 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1210081.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，领航医药生物科技(00399)公布，于2024年11月12日，该公司作为投资者已与目标(Niraxx. Inc.)订立谅解备忘录，表明公司有意就有关目标的大多数股权的潜在投资对目标进行投资。据悉，目标为一间于美国德拉瓦州注册成立的有限公司，主要从事(a)开发人工智能驱动的虚拟健康平台SyncWell;(b)开发脑神经技术服务平台DeepSynaps;(c) 于运动服融入光生物调节...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1210081.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1124","symbol_name":"贸易公司与经销商","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1210081.html","article_id":"2482702214","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482702214","pubTimestamp":1731417710,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，领航医药生物科技 公布，于2024年11月12日，该公司作为投资者已与目标订立谅解备忘录，表明公司有意就有关目标的大多数股权的潜在投资对目标进行投资。董事会认为潜在投资及订立正式协议代表集团发展其业务的策略举措及预期与目标展开长期合作，此举不仅将有助于进一步多元化集团的业务，且将扩大并与集团现有业务产生协同效应，亦预期为集团带来新利润增长点。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1124":"贸易公司与经销商","00399":"领航医药生物科技"},"translate_title":"Linghang Pharmaceutical Biotechnology (00399) plans to acquire Niraxx. Inc. majority ownership","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00399":1},"content_text":"智通财经APP讯，领航医药生物科技(00399)公布，于2024年11月12日，该公司作为投资者已与目标(Niraxx. Inc.)订立谅解备忘录，表明公司有意就有关目标的大多数股权的潜在投资对目标进行投资。据悉，目标为一间于美国德拉瓦州注册成立的有限公司，主要从事(a)开发人工智能驱动的虚拟健康平台SyncWell;(b)开发脑神经技术服务平台DeepSynaps;(c) 于运动服融入光生物调节技术;及(d)开发整合先进技术的电脑芯片。董事会认为潜在投资及订立正式协议代表集团发展其业务的策略举措及预期与目标展开长期合作，此举不仅将有助于进一步多元化集团的业务，且将扩大并与集团现有业务产生协同效应，亦预期为集团带来新利润增长点。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482702214"}